SCHEMBL478933

SCHEMBL478933

CC(=O)c1ccc(N)c(F)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.61
HDAC6 Q9UBN7 1/20 0.61
PRKCI P41743 1/20 0.52
CREBBP Q92793 1/20 0.47
ALDH1A1 P00352 1/20 0.46
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43
SLC6A5 Q9Y345 1/20 0.43
NPC1 O15118 2/20 0.42
MAPT P10636 2/20 0.42
RAB9A P51151 2/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA4 P22748 1/20 0.42
CA6 P23280 1/20 0.42
CA5A P35218 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29388181 1.00 HDAC1 (0.61) HDAC1HDAC6PRKCICREBBPALDH1A1
SCHEMBL5332682 0.85 HDAC1 (0.47) HDAC1HDAC6PRKCICREBBPALDH1A1
SCHEMBL935912 0.83 PRKCI (0.56) HDAC1HDAC6PRKCICREBBPALDH1A1
SCHEMBL863794 0.83 HDAC1 (0.66) HDAC1HDAC6ALDH1A1CES2CES1
SCHEMBL29367661 0.81 HDAC1 (0.63) HDAC1HDAC6ALDH1A1CES2CES1
SCHEMBL1627106 0.81 HDAC1 (0.63) HDAC1HDAC6ALDH1A1CES2CES1
SCHEMBL97816 0.81 HDAC1 (0.63) HDAC1HDAC6ALDH1A1CES2CES1
SCHEMBL4453036 0.81 MAPT (0.61) HDAC1HDAC6ALDH1A1MAPTRAB9A
SCHEMBL29669896 0.80 CES2 (0.67) CES2CES1NPC1MAPTRAB9A
SCHEMBL75801 0.80 CES2 (0.67) CES2CES1NPC1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820746-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2023-11-21 US disclosed
US-20230348384-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2023-11-02 US disclosed
US-11192859-B2 Quinoline compounds as modulators of RAGE activity and uses thereof UNIV NEW YORK (US) 2021-12-07 US disclosed
US-20190194136-A1 QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF UNIV NEW YORK (US) 2019-06-27 US disclosed
WO-2018122232-A1 (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES UCB PHARMA GMBH (DE) 2018-07-05 WO disclosed
WO-2017184547-A1 QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF NEW YORK UNIVERSITY (US) 2017-10-26 WO disclosed
CN-102026996-B Pyridazine derivatives as factor XIA inhibitors BRISTOL MYERS SQUIBB CO 2015-01-07 CN disclosed
US-20130190492-A1 SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES ENDO PHARMACEUTICALS INC. (US) 2013-07-25 US disclosed
EP-1861357-B1 NOVEL COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AMOREPACIFIC CORP (KR) 2013-04-24 EP disclosed
EP-1861357-B1 NOVEL COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AMOREPACIFIC CORP (KR) 2013-04-24 EP disclosed
US-6608095-B2 Sulfonylbenzene and sulfonamidobenzene compounds which inhibit COX-2; treatment of a medical condition in which prostaglandins are implicated as pathogens PFIZER INC. 2003-08-19 US disclosed
US-20020045654-A1 Sulfonylbenzene compounds as anti-inflammatory/analgesic agents ANDO KAZUO (JP) 2002-04-18 US disclosed
US-6294558-B1 ANTIINFLAMMATORY AGENTS AND PROSTAGLANTINS PFIZER INC. 2001-09-25 US disclosed
EP-1086097-A1 SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS PFIZER INC. (US) 2001-03-28 EP disclosed
WO-1999064415-A1 SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS PFIZER PHARMACEUTICALS INC. (JP) 1999-12-16 WO disclosed
US-4333940-A Ring-fluorinated 4-(monosubstituted-amino) phenyl compounds in inhibiting atherosclerotic lesion development AMERICAN CYANAMID COMPANY (US) 1982-06-08 US disclosed
US-4243609-A ANTILIPEMIC AGENTS, ANTIATHEROSCLEROTIC AGENTS AMERICAN CYANAMID COMPANY (US) 1981-01-06 US disclosed
EP-0003663-A2 Amino-substituted phenyl and heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them AMERICAN CYANAMID COMPANY (US) 1979-08-22 EP disclosed
US-4122070-A Fibers and anisotropic melts of polyazomethines E. I. DU PONT DE NEMOURS AND COMPANY (US) 1978-10-24 US disclosed
US-4048148-A Polyazomethine fibers and films E. I. DU PONT DE NEMOURS AND COMPANY (US) 1977-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11820746-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides GPR17, GPR18, GPR27 HDAC1 777/4885HDAC6 527/4885PRKCI 4707/4885
US-20230348384-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides GPR17, GPR18, GPR27 HDAC1 777/4885HDAC6 527/4885PRKCI 4707/4885
US-20130190492-A1 SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES MTOR, PIK3CA, PDPK1 HDAC1 1203/4885HDAC6 2022/4885PRKCI 1324/4885
US-20020045654-A1 Sulfonylbenzene compounds as anti-inflammatory/analgesic agents CNR1, PTGER1, PTGS1 HDAC1 1268/4885HDAC6 1674/4885PRKCI 2256/4885
US-20190194136-A1 QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF AGER, HMGB1, GPR119 HDAC1 3999/4885HDAC6 3963/4885PRKCI 3270/4885
US-11192859-B2 Quinoline compounds as modulators of RAGE activity and uses thereof AGER, HMGB1, GPR119 HDAC1 3999/4885HDAC6 3963/4885PRKCI 3270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.